John Libbey Eurotext

Innovations & Thérapeutiques en Oncologie

MENU

General presentation of non-small cell lung cancer Volume 4, issue 4, Juillet-Août 2018

Tables

Author
Centre Oscar Lambret
3, rue Frédéric Combemale
BP 307 - 59020 Lille Cedex
France
* Tirés à part
  • Key words: metastatic non-small cell lung cancer, incidence, mortality, immunotherapy
  • DOI : 10.1684/ito.2018.0131
  • Page(s) : 187-8
  • Published in: 2018

Lung cancer is a major public health problem. It remains the leading cause of cancer mortality worldwide. In France, lung cancer causes nearly 30,000 deaths a year. Survival and quality of life of metastatic NSCLC patients can be improved by targeting oncogenic molecular alterations with specific agents and using immunotherapy to suppress the inhibition of immune response, mediated by PD-L1 or PD-1, to reactivate the antitumour immune response. Immunotherapy changes the way in which metastatic NSCLC is managed and raises questions about the management of toxicity, relevant biomarkers, optimal development, and costs.